KIORA PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $14.70M
- P/E (TTM)
- –
- Dividend yield
- –
About Kiora Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for retinal diseases. Its primary product candidates include KIO-301, a small-molecule photoswitch designed to restore light sensitivity in patients suffering from inherited and age-related retinal degenerations like retinitis pigmentosa, and KIO-104, a dihydroorotate dehydrogenase inhibitor formulated for intravitreal injection to treat retinal inflammatory conditions such as diabetic macular edema and posterior non-infectious uveitis. The company also maintains KIO-101, a topical eye drop formulation aimed at addressing ocular manifestations of autoimmune disorders. Its prospective end users encompass individuals experiencing severe or degenerative vision impairments.
The company operates globally through strategic development partnerships and licensing arrangements across North America, Europe, and Asia, including collaborations with entities such as Théa Open Innovation and Senju Pharmaceutical. Clinical studies have been conducted at medical sites in Australia. The provided text details international clinical and commercial collaboration rights without specifying physical facility counts or a headquarters location.
Summary of the business section of Kiora Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- KIORA PHARMACEUTICALS INC
- Founded
- 1998
- Headquarters
- Encinitas, CA
- Address
- 169 Saxony Rd., Suite 212 92024
- Phone
- (858) 224-9600
- Website
- kiorapharma.com
- Employees
- 3,500, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- KPRX
- Other tickers
- KPHMW
- Exchange
- Nasdaq
- IPO date
- Feb 13, 2015
- Shares outstanding
- 4M, Aug 5, 2026
- Public float
- $10.47M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-9 reverse, Jun 11, 2024; 1-for-9 reverse, Jun 11, 2024; 1-for-40 reverse, Sep 27, 2022; 1-for-41 reverse, Aug 12, 2022; 1-for-15 reverse, Aug 30, 2019
- SEC CIK
- 1372514
- CUSIP
- 49721T507
- ISIN
- US49721T5074
- LEI
- 549300395G8DB8ZFV365
- EIN
- 98-0443284
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian M. Strem | President and CEO, Director | 58,823 |
| Melissa Tosca | CFO | 26,064 |
| Eric Joseph Daniels | Chief Development Officer | 31,741 |
| Lisa Walters-Hoffert | Director | 1,250 |
| Aron Shapiro | Director | 3,000 |
| Erin Parsons | Director | 5,260 |
| Carmine N. Stengone | Director | 1,250 |
| Praveen Tyle | Director | 5,014 |
| David Hollander | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 First PEO | $0 | $0 | $737.12K | $-40 | – |
| FY2025 Second PEO | $971.70K | $949.28K | $737.12K | $-40 | – |
| FY2024 First PEO | $0 | $0 | $604.12K | $-30 | – |
| FY2024 Second PEO | $954.88K | $948.83K | $604.12K | $-30 | – |
| FY2023 First PEO | $546.15K | $546.15K | $530.15K | $-85 | – |
| FY2023 Second PEO | $805.25K | $710.29K | $530.15K | $-85 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“RP affects about 1 in 3,500 people worldwide.”
Corporate history
Events identified from SEC filings